Ji Ma

1.2k total citations
40 papers, 620 citations indexed

About

Ji Ma is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Ji Ma has authored 40 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Molecular Biology and 11 papers in Hematology. Recurrent topics in Ji Ma's work include Platelet Disorders and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Chemokine receptors and signaling (4 papers). Ji Ma is often cited by papers focused on Platelet Disorders and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Chemokine receptors and signaling (4 papers). Ji Ma collaborates with scholars based in China, United States and Canada. Ji Ma's co-authors include Man Hu, Jun Peng, Bingjie Fan, Ming Hou, Song Xue, Li Xie, Feifei Teng, Dianbin Mu, Yufang Zhu and Miao Xu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Ji Ma

39 papers receiving 614 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ji Ma China 16 197 166 133 106 104 40 620
M.A. Argiriadi United States 13 357 1.8× 178 1.1× 124 0.9× 77 0.7× 161 1.5× 22 971
Kathleen M. Gillooly United States 14 263 1.3× 166 1.0× 263 2.0× 53 0.5× 145 1.4× 17 778
Roberta Pireddu United States 10 465 2.4× 240 1.4× 100 0.8× 132 1.2× 96 0.9× 14 718
Filippa Pettersson Canada 18 654 3.3× 220 1.3× 90 0.7× 73 0.7× 49 0.5× 26 884
Xiang-ju Gu United States 11 522 2.6× 197 1.2× 70 0.5× 55 0.5× 116 1.1× 12 911
Enrique Poradosu United States 10 308 1.6× 135 0.8× 51 0.4× 80 0.8× 86 0.8× 17 556
Lori Capone Switzerland 9 466 2.4× 179 1.1× 399 3.0× 307 2.9× 68 0.7× 13 1.0k
Darcy Bates United States 12 391 2.0× 185 1.1× 71 0.5× 24 0.2× 91 0.9× 17 704
Tadakazu Akiyama Japan 15 561 2.8× 303 1.8× 84 0.6× 116 1.1× 117 1.1× 17 832
Eiji Nishiwaki Japan 14 395 2.0× 190 1.1× 84 0.6× 52 0.5× 195 1.9× 17 787

Countries citing papers authored by Ji Ma

Since Specialization
Citations

This map shows the geographic impact of Ji Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ji Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ji Ma more than expected).

Fields of papers citing papers by Ji Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ji Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ji Ma. The network helps show where Ji Ma may publish in the future.

Co-authorship network of co-authors of Ji Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Ji Ma. A scholar is included among the top collaborators of Ji Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ji Ma. Ji Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Ji, et al.. (2022). Ixazomib Combined With Autologous Stem Cell Transplantation for POEMS Syndrome: A Case Report and Meta-Analysis. Technology in Cancer Research & Treatment. 21. 2213865522–2213865522. 2 indexed citations
2.
Qin, Jing, Qiang Liu, Anli Liu, et al.. (2022). Empagliflozin modulates CD4+ T‐cell differentiation via metabolic reprogramming in immune thrombocytopenia. British Journal of Haematology. 198(4). 765–775. 18 indexed citations
3.
Wu, Wenjun, Pin Lu, Priyal Patel, et al.. (2022). SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker. Oncogene. 42(6). 409–420. 4 indexed citations
4.
Ma, Ji, Yaru Tian, Wei‐Bo Hu, et al.. (2022). Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis. Journal of Neuro-Oncology. 159(3). 685–693. 7 indexed citations
5.
Tian, Yaru, Ji Ma, Xiaoyang Zhai, et al.. (2022). Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy. Cancer Letters. 541. 215719–215719. 34 indexed citations
6.
Li, Xin, Yuanxin Sun, Yuanjian Wang, et al.. (2020). Human leukocyte antigen-G upregulates immunoglobulin-like transcripts and corrects dysfunction of immune cells in immune thrombocytopenia. Haematologica. 106(3). 770–781. 12 indexed citations
7.
Reed, Anthony B., Brian A. Lanman, Jerry Ryan Holder, et al.. (2020). Half-life extension of peptidic APJ agonists by N-terminal lipid conjugation. Bioorganic & Medicinal Chemistry Letters. 30(21). 127499–127499. 8 indexed citations
8.
Shi, Jianxia, et al.. (2017). Reagent-Free LC–MS/MS-Based Pharmacokinetic Quantification of Polyhistidine-Tagged Therapeutic Proteins. Bioanalysis. 9(3). 251–264. 4 indexed citations
9.
Xue, Song, Man Hu, Jinming Yu, Bingjie Fan, & Ji Ma. (2017). Correlation of PD-L1 with VEGF and KI-67 index in patients with primary glioma.. Journal of Clinical Oncology. 35(7_suppl). 94–94. 2 indexed citations
10.
Min, Yanan, Chi‐Yuen Wang, Xiaoxi Li, et al.. (2016). Participation of B‐cell‐activating factor receptors in the pathogenesis of immune thrombocytopenia. Journal of Thrombosis and Haemostasis. 14(3). 559–571. 15 indexed citations
11.
Hu, Essa, Ning Chen, Roxanne K. Kunz, et al.. (2016). Discovery of Phosphodiesterase 10A (PDE10A) PET Tracer AMG 580 to Support Clinical Studies. ACS Medicinal Chemistry Letters. 7(7). 719–723. 4 indexed citations
12.
Zhang, Xiaolin, Ji Ma, Miao Xu, et al.. (2014). Imbalance between CD205 and CD80/CD86 in dendritic cells in patients with immune thrombocytopenia. Thrombosis Research. 135(2). 352–361. 10 indexed citations
13.
Zhang, Yaping, Cheng‐Pang Hsu, Jianfeng Lü, et al.. (2014). FLT3 and CDK4/6 inhibitors: Signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. Journal of Pharmacokinetics and Pharmacodynamics. 41(6). 675–691. 9 indexed citations
14.
Ma, Ji, Qi Wu, Yue Zhang, et al.. (2014). microRNA sponge blocks the tumor-suppressing functions of microRNA-122 in human hepatoma and osteosarcoma cells. Oncology Reports. 32(6). 2744–2752. 11 indexed citations
15.
Ma, Ji, Zongtang Liu, Aixia Dou, et al.. (2013). Characterization of Th1- and Th2-associated Chemokine Receptor Expression in Spleens of Patients with Immune Thrombocytopenia. Journal of Clinical Immunology. 33(5). 938–946. 11 indexed citations
16.
Cho, Robert, Yingying Huang, Jae C. Schwartz, et al.. (2012). MSM, an Efficient Workflow for Metabolite Identification Using Hybrid Linear Ion Trap Orbitrap Mass Spectrometer. Journal of the American Society for Mass Spectrometry. 23(5). 880–888. 15 indexed citations
17.
Dai, Kang, Cong Li, Lingming Liang, et al.. (2012). Abstract LB-249: Characterization of a novel potent and selective CDK4/6 inhibitor and a resistance mechanism. Cancer Research. 72(8_Supplement). LB–249. 1 indexed citations
18.
Chen, Xiaoqi, Jeff Mihalic, Darin J. Gustin, et al.. (2011). Discovery of potent and specific CXCR3 antagonists. Bioorganic & Medicinal Chemistry Letters. 22(1). 357–362. 14 indexed citations
19.
Du, Xiaohui, Darin J. Gustin, Xiaoqi Chen, et al.. (2009). Imidazo-pyrazine derivatives as potent CXCR3 antagonists. Bioorganic & Medicinal Chemistry Letters. 19(17). 5200–5204. 29 indexed citations
20.
Du, Xiaohui, Xiaoqi Chen, Jason Duquette, et al.. (2007). Design and optimization of imidazole derivatives as potent CXCR3 antagonists. Bioorganic & Medicinal Chemistry Letters. 18(2). 608–613. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M.A. Argiriadi Breakdown of academic impact, for papers by Kathleen M. Gillooly Breakdown of academic impact, for papers by Roberta Pireddu Breakdown of academic impact, for papers by Filippa Pettersson Breakdown of academic impact, for papers by Xiang-ju Gu Breakdown of academic impact, for papers by Enrique Poradosu Breakdown of academic impact, for papers by Lori Capone Breakdown of academic impact, for papers by Darcy Bates Breakdown of academic impact, for papers by Tadakazu Akiyama Breakdown of academic impact, for papers by Eiji Nishiwaki
Rankless by CCL
2026